Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other financing activities (2016 - 2022)

Historic Other financing activities for Syndax Pharmaceuticals (SNDX) over the last 8 years, with Q1 2022 value amounting to $92000.0.

  • Syndax Pharmaceuticals' Other financing activities rose 1645.57% to $92000.0 in Q1 2022 from the same period last year, while for Mar 2022 it was $13000.0, marking a year-over-year decrease of 1875.0%. This contributed to the annual value of $1000.0 for FY2020, which is 9945.05% down from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Other financing activities of $92000.0 as of Q1 2022, which was up 1645.57% from -$242000.0 recorded in Q4 2021.
  • In the past 5 years, Syndax Pharmaceuticals' Other financing activities registered a high of $207000.0 during Q4 2018, and its lowest value of -$242000.0 during Q4 2020.
  • In the last 5 years, Syndax Pharmaceuticals' Other financing activities had a median value of $63000.0 in 2018 and averaged $35941.2.
  • Per our database at Business Quant, Syndax Pharmaceuticals' Other financing activities skyrocketed by 350000.0% in 2018 and then crashed by 52456.14% in 2020.
  • Syndax Pharmaceuticals' Other financing activities (Quarter) stood at $207000.0 in 2018, then plummeted by 72.46% to $57000.0 in 2019, then crashed by 524.56% to -$242000.0 in 2020, then changed by 0.0% to -$242000.0 in 2021, then surged by 138.02% to $92000.0 in 2022.
  • Its last three reported values are $92000.0 in Q1 2022, -$242000.0 for Q4 2021, and $99000.0 during Q3 2021.